CN116925222A - 抗pvrig抗体、其药物组合物及用途 - Google Patents

抗pvrig抗体、其药物组合物及用途 Download PDF

Info

Publication number
CN116925222A
CN116925222A CN202210343374.8A CN202210343374A CN116925222A CN 116925222 A CN116925222 A CN 116925222A CN 202210343374 A CN202210343374 A CN 202210343374A CN 116925222 A CN116925222 A CN 116925222A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
antibody
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210343374.8A
Other languages
English (en)
Chinese (zh)
Inventor
翟天航
戴爽
黄威峰
曾竣玮
约翰·布考斯基
凯文·舒茨
梅根·黑默莱恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotheus Inc
Original Assignee
Biotheus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotheus Inc filed Critical Biotheus Inc
Priority to CN202210343374.8A priority Critical patent/CN116925222A/zh
Priority to EP23778428.5A priority patent/EP4506360A4/en
Priority to JP2024558263A priority patent/JP2025511288A/ja
Priority to US18/852,907 priority patent/US20250223353A1/en
Priority to PCT/CN2023/085357 priority patent/WO2023186063A1/zh
Priority to CA3256036A priority patent/CA3256036A1/en
Priority to KR1020247036668A priority patent/KR20240168451A/ko
Priority to AU2023243878A priority patent/AU2023243878A1/en
Priority to CN202380031274.4A priority patent/CN118946588A/zh
Publication of CN116925222A publication Critical patent/CN116925222A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CN202210343374.8A 2022-04-02 2022-04-02 抗pvrig抗体、其药物组合物及用途 Pending CN116925222A (zh)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CN202210343374.8A CN116925222A (zh) 2022-04-02 2022-04-02 抗pvrig抗体、其药物组合物及用途
EP23778428.5A EP4506360A4 (en) 2022-04-02 2023-03-31 Anti-PVRIG antibodies, pharmaceutical composition and associated uses
JP2024558263A JP2025511288A (ja) 2022-04-02 2023-03-31 抗ｐｖｒｉｇ抗体、その医薬組成物及びその使用
US18/852,907 US20250223353A1 (en) 2022-04-02 2023-03-31 Anti-pvrig antibody, pharmaceutical composition thereof and use thereof
PCT/CN2023/085357 WO2023186063A1 (zh) 2022-04-02 2023-03-31 抗pvrig抗体、其药物组合物及用途
CA3256036A CA3256036A1 (en) 2022-04-02 2023-03-31 Anti-PVRIG antibodies, pharmaceutical composition and associated uses
KR1020247036668A KR20240168451A (ko) 2022-04-02 2023-03-31 항-pvrig 항체, 이의 약제학적 조성물 및 이의 용도
AU2023243878A AU2023243878A1 (en) 2022-04-02 2023-03-31 Anti-pvrig antibody, pharmaceutical composition thereof and use thereof
CN202380031274.4A CN118946588A (zh) 2022-04-02 2023-03-31 抗pvrig抗体、其药物组合物及用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210343374.8A CN116925222A (zh) 2022-04-02 2022-04-02 抗pvrig抗体、其药物组合物及用途

Publications (1)

Publication Number Publication Date
CN116925222A true CN116925222A (zh) 2023-10-24

Family

ID=88199482

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210343374.8A Pending CN116925222A (zh) 2022-04-02 2022-04-02 抗pvrig抗体、其药物组合物及用途
CN202380031274.4A Pending CN118946588A (zh) 2022-04-02 2023-03-31 抗pvrig抗体、其药物组合物及用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202380031274.4A Pending CN118946588A (zh) 2022-04-02 2023-03-31 抗pvrig抗体、其药物组合物及用途

Country Status (8)

Country Link
US (1) US20250223353A1 (https=)
EP (1) EP4506360A4 (https=)
JP (1) JP2025511288A (https=)
KR (1) KR20240168451A (https=)
CN (2) CN116925222A (https=)
AU (1) AU2023243878A1 (https=)
CA (1) CA3256036A1 (https=)
WO (1) WO2023186063A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119591715A (zh) * 2023-12-22 2025-03-11 华润生物医药有限公司 抗pvrig抗体及其用途
CN120025447A (zh) * 2023-11-23 2025-05-23 广东菲鹏制药股份有限公司 抗人pvrig抗体及其应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116135884A (zh) * 2021-11-17 2023-05-19 普米斯生物技术(珠海)有限公司 抗tigit-抗pd-l1双特异性抗体、其药物组合物及用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
KR102318383B1 (ko) 2010-07-16 2021-10-27 아디맵 엘엘씨 항체 라이브러리
KR102236367B1 (ko) 2013-07-26 2021-04-05 삼성전자주식회사 DARPin을 포함하는 이중 특이 키메라 단백질
CA2942546C (en) 2014-03-17 2022-11-22 Mitsubishi Tanabe Pharma Corporation Antibody-fynomer conjugates
DK3653221T5 (da) 2015-02-19 2024-08-26 Compugen Ltd Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
US10407484B2 (en) * 2015-09-02 2019-09-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for modulating T-cell mediated immune response
JP7348072B2 (ja) * 2017-06-01 2023-09-20 コンピュジェン リミテッド 三重併用抗体療法
KR20210016448A (ko) * 2018-06-01 2021-02-15 컴퓨젠 엘티디. 항-pvrig/항-tigit 이중특이적 항체 및 사용 방법
MX2021000745A (es) * 2018-07-20 2021-03-26 Surface Oncology Inc Composiciones anti-cd112r y metodos.
CN113164766B (zh) 2018-10-23 2025-02-25 供石公司 RGMc选择性抑制剂及其用途
CA3170025A1 (en) * 2020-03-13 2021-09-16 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pvrig binding protein and its medical uses

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120025447A (zh) * 2023-11-23 2025-05-23 广东菲鹏制药股份有限公司 抗人pvrig抗体及其应用
WO2025108395A1 (zh) * 2023-11-23 2025-05-30 广东菲鹏制药股份有限公司 抗人pvrig抗体及其应用
CN119591715A (zh) * 2023-12-22 2025-03-11 华润生物医药有限公司 抗pvrig抗体及其用途
CN119841952A (zh) * 2023-12-22 2025-04-18 华润生物医药有限公司 抗pvrig抗体及其用途
CN119591715B (zh) * 2023-12-22 2025-10-31 华润生物医药有限公司 抗pvrig抗体及其用途
CN119841952B (zh) * 2023-12-22 2025-11-04 华润生物医药有限公司 抗pvrig抗体及其用途

Also Published As

Publication number Publication date
WO2023186063A1 (zh) 2023-10-05
AU2023243878A2 (en) 2024-11-14
AU2023243878A1 (en) 2024-11-07
US20250223353A1 (en) 2025-07-10
CA3256036A1 (en) 2025-06-17
EP4506360A4 (en) 2026-04-08
CN118946588A (zh) 2024-11-12
KR20240168451A (ko) 2024-11-29
JP2025511288A (ja) 2025-04-15
EP4506360A1 (en) 2025-02-12

Similar Documents

Publication Publication Date Title
RU2693661C2 (ru) Антитело против pdl-1, его фармацевтическая композиция и применение
JP7425604B2 (ja) 抗ｃｔｌａ４－抗ｐｄ－１二機能性抗体、その医薬組成物および使用
RU2739610C1 (ru) Антитело против PD-1 и его применение
KR20220057558A (ko) 항-cd73 항체
US20240352153A1 (en) Pharmaceutical composition and use
EP4506365A1 (en) Anti-tigit/anti-pvrig bispecific antibody, and pharmaceutical composition and use thereof
CN114478769B (zh) 抗tigit抗体、其药物组合物及用途
EP4506360A1 (en) Anti-pvrig antibody, pharmaceutical composition thereof and use thereof
EP4435010A1 (en) Bispecific antibody against tigit and pd-l1, and pharmaceutical composition thereof and use thereof
JP2024532836A (ja) 抗ＴＩＧＩＴ抗体及びＴＧＦ－βＲを含む融合タンパク質、並びにその医薬組成物及び使用
JP2026508210A (ja) ＴＧＦ－βＲＩＩ細胞外領域断片を含む融合タンパク質、その医薬組成物、およびその使用
HK40093009A (en) Anti-tigit antibody, and pharmaceutical composition and use thereof
HK40089230A (zh) 药物组合物及用途
EA049283B1 (ru) Антитело к tigit и его фармацевтическая композиция и применение
EA042365B1 (ru) Бифункциональное антитело против ctla4 и против pd-1, его фармацевтическая композиция и их применение

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Country or region after: China

Address after: 519080 Guangdong Province, Zhuhai City, Xiangzhou District, Tangjia Bay Town, Keji 7th Road No. 1, Building 4, Unit 10-B

Applicant after: Baiou En Tai (Zhuhai) Pharmaceutical R&D Co.,Ltd.

Address before: 519080 Guangdong Province, Zhuhai City, Xiangzhou District, Tangjia Bay Town, Keji 7th Road No. 1, Building 4, Unit 10-B

Applicant before: Pumis Biotechnology (Zhuhai) Co.,Ltd.

Country or region before: China

CB02 Change of applicant information